Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Tp53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma.

Bossi P, Perrone F, Miceli R, Cantù G, Mariani L, Orlandi E, Fallai C, Locati LD, Cortelazzi B, Quattrone P, Potepan P, Licitra L, Pilotti S.

Oral Oncol. 2013 May;49(5):413-9. doi: 10.1016/j.oraloncology.2012.12.011. Epub 2013 Jan 29.

PMID:
23369851
2.

Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma.

Licitra L, Suardi S, Bossi P, Locati LD, Mariani L, Quattrone P, Lo Vullo S, Oggionni M, Olmi P, Cantù G, Pierotti MA, Pilotti S.

J Clin Oncol. 2004 Dec 15;22(24):4901-6.

PMID:
15611505
3.
4.

Cisplatin-based neoadjuvant chemotherapy and combined resection for ethmoid sinus adenocarcinoma reaching and/or invading the skull base.

Brasnu D, Laccourreye O, Bassot V, Laccourreye L, Naudo P, Roux FX.

Arch Otolaryngol Head Neck Surg. 1996 Jul;122(7):765-8.

PMID:
8663951
5.

Adenocarcinoma of the ethmoid sinus: retrospective study of 42 cases.

Breheret R, Laccourreye L, Jeufroy C, Bizon A.

Eur Ann Otorhinolaryngol Head Neck Dis. 2011 Nov;128(5):211-7. doi: 10.1016/j.anorl.2011.02.012. Epub 2011 May 26.

6.

Postoperative chemotherapy vs chemoradiotherapy for thoracic esophageal cancer: a prospective randomized clinical trial.

Tachibana M, Yoshimura H, Kinugasa S, Shibakita M, Dhar DK, Ueda S, Fujii T, Nagasue N.

Eur J Surg Oncol. 2003 Sep;29(7):580-7.

PMID:
12943623
7.

Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.

Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J Jr, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R.

Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):427-36.

PMID:
15380576
8.

Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision.

Donada M, Bonin S, Barbazza R, Pettirosso D, Stanta G.

BMC Gastroenterol. 2013 Feb 27;13:36. doi: 10.1186/1471-230X-13-36.

9.

Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma.

Song CH, Wu HG, Heo DS, Kim KH, Sung MW, Park CI.

Laryngoscope. 2008 Apr;118(4):663-70. doi: 10.1097/MLG.0b013e3181626cfe.

PMID:
18216741
10.

Endoscopic resection followed by adjuvant radiotherapy for sinonasal intestinal-type adenocarcinoma: Retrospective analysis of 30 consecutive patients.

Antognoni P, Turri-Zanoni M, Gottardo S, Molteni M, Volpi L, Facco C, Freguia S, Mordacchini C, AlQahtani A, Bignami M, Capella C, Castelnuovo P.

Head Neck. 2015 May;37(5):677-84. doi: 10.1002/hed.23660. Epub 2014 Apr 30.

PMID:
24596075
11.

Stage III-IV sinonasal and nasal cavity carcinoma treated with three-dimensional conformal radiotherapy.

Gabriele AM, Airoldi M, Garzaro M, Zeverino M, Amerio S, Condello C, Trotti AB.

Tumori. 2008 May-Jun;94(3):320-6.

12.

Evaluation of p53 protein as a prognostic factor for oral cancer surgery.

Cutilli T, Leocata P, Dolo V, Altobelli E.

Br J Oral Maxillofac Surg. 2013 Dec;51(8):922-7. doi: 10.1016/j.bjoms.2013.05.150. Epub 2013 Jun 20.

PMID:
23791033
13.

Lymph node metastasis in sinonasal squamous cell carcinoma treated with IMRT/3D-CRT.

Guan X, Wang X, Liu Y, Hu C, Zhu G.

Oral Oncol. 2013 Jan;49(1):60-5. doi: 10.1016/j.oraloncology.2012.07.009. Epub 2012 Aug 9.

PMID:
22884302
14.

Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.

Chang MH, Lee IK, Si Y, Lee KS, Woo IS, Byun JH.

Cancer Chemother Pharmacol. 2011 Aug;68(2):317-23. doi: 10.1007/s00280-010-1496-5. Epub 2010 Oct 24.

PMID:
20972872
15.

A phase I/II trial of three-dimensionally planned concurrent boost radiotherapy and protracted venous infusion of 5-FU chemotherapy for locally advanced rectal carcinoma.

Myerson RJ, Valentini V, Birnbaum EH, Cellini N, Coco C, Fleshman JW, Gambacorta MA, Genovesi D, Kodner IJ, Picus J, Ratkin GA, Read TE.

Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1299-308.

PMID:
11483342
16.

Ethmoid adenocarcinoma--from craniofacial to endoscopic resections: a single-institution experience over 25 years.

Nicolai P, Villaret AB, Bottazzoli M, Rossi E, Valsecchi MG.

Otolaryngol Head Neck Surg. 2011 Aug;145(2):330-7. doi: 10.1177/0194599811403873. Epub 2011 Apr 22.

PMID:
21515803
17.

Can p53 alterations be used to predict tumour response to pre-operative chemo-radiotherapy in locally advanced rectal cancer?

Elsaleh H, Robbins P, Joseph D, Powell B, Grieu F, Menso L, Iacopetta B.

Radiother Oncol. 2000 Aug;56(2):239-44.

PMID:
10927144
18.

[Cancer of the ethmoid sinus].

Brasnu D, Roux FX.

Rev Prat. 2000 Sep 15;50(14):1562-5. French.

PMID:
11068621
19.

TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma.

Perrone F, Bossi P, Cortelazzi B, Locati L, Quattrone P, Pierotti MA, Pilotti S, Licitra L.

J Clin Oncol. 2010 Feb 10;28(5):761-6. doi: 10.1200/JCO.2009.22.4170. Epub 2010 Jan 4.

PMID:
20048189
20.

Ethmoid sinus carcinomas: results and prognosis after neoadjuvant chemotherapy and combined surgery--a 10-year experience.

Roux FX, Brasnu D, Devaux B, Chabardes E, Schwaab G, Laccourreye O, Menard M, Janot F, Nguyen S, Bertrand J, et al.

Surg Neurol. 1994 Aug;42(2):98-104.

PMID:
8091301

Supplemental Content

Support Center